Payment overview · 2025
General Payments
$55,432.32
199 reported records · 27 companies
Healthcare provider profile · identity verified
Minh Q Mach, M.D.
Allopathic & Osteopathic Physicians|General Practice · TOLUCA LAKE, CA · NPI 1831298736
Verified facts
What the public records show
CMS Open Payments records show Minh Q Mach, M.D. received $55,432.32 in general payments during 2025 across 199 reported records.
Lilly USA, LLC accounted for 81.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 357 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 357 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tymlos by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45,289.83 | 81.7% | 61 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5,852.07 | 10.6% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,057.55 | 1.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $881.10 | 1.6% | 27 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $355.06 | 0.6% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $332.06 | 0.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $318.84 | 0.6% | 16 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $219.93 | 0.4% | 9 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $208.84 | 0.4% | 10 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $137.55 | 0.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.21 | 0.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.58 | 0.2% | 3 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.10 | 0.1% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $76.28 | 0.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$70.28 | 0.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $48.44 | 0.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $46.50 | 0.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.43 | 0.1% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $34.49 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.38 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.88 | 0.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $31.48 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.92 | 0.1% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.51 | 0.0% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $23.38 | 0.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.54 | 0.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.09 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,100.00 | 52 |
| Food and Beverage | $3,970.16 | 142 |
| Consulting Fee | $1,000.00 | 1 |
| Travel and Lodging | $319.66 | 3 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39,040.24 | 46 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $11,767.24 | 26 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $1,057.55 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $881.10 | 27 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $355.06 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $209.42 | 12 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $208.84 | 10 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $208.84 | 10 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $208.84 | 10 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $200.32 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $163.99 | 8 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $137.55 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $134.34 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $90.21 | 3 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $87.58 | 3 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $77.10 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $76.28 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $70.28 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $48.44 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $46.50 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $34.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $33.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.44 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 357 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 245 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 315 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
357 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
357 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
245 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
219 | 46 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
315 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 832 | 209 |
| Pioglitazone Hcl | Pioglitazone Hcl | 597 | 143 |
| Jardiance | Empagliflozin | 357 | 77 |
| Ozempic | Semaglutide | 315 | 68 |
| Mounjaro | Tirzepatide | 245 | 46 |
| Trulicity | Dulaglutide | 219 | 46 |
| Synthroid | Levothyroxine Sodium | 196 | 54 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 183 | 33 |
| Tradjenta | Linagliptin | 179 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 50 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 166 | 72 |
| Farxiga | Dapagliflozin Propanediol | 165 | 31 |
| Metformin Hcl | Metformin Hcl | 164 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 42 |
| Januvia | Sitagliptin Phosphate | 140 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 139 | 38 |
| Losartan Potassium | Losartan Potassium | 138 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 133 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 37 |
| Nateglinide | Nateglinide | 122 | 30 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 119 | 16 |
| Glimepiride | Glimepiride | 118 | 26 |
| Glyxambi | Empagliflozin/Linagliptin | 106 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 104 | 23 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 85 | 22 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 82 | 16 |
| Novolog Flexpen | Insulin Aspart | 80 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 71 | 24 |
| Methimazole | Methimazole | 71 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 21 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 66 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 17 |
| Simvastatin | Simvastatin | 58 | 16 |
| Gabapentin | Gabapentin | 57 | 14 |
| Cinacalcet Hcl | Cinacalcet Hcl | 52 | 12 |
| Alendronate Sodium | Alendronate Sodium | 51 | 14 |
| Humalog | Insulin Lispro | 46 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 45 | suppressed |
| Novolog | Insulin Aspart | 45 | 14 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Lisinopril | Lisinopril | 41 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 41 | 14 |
| Testosterone | Testosterone | 41 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Admelog Solostar | Insulin Lispro | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Afrezza | Insulin Regular, Human | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55,432.32 · 199 records | Lilly USA, LLC | AFREZZA, CONTRAVE, CRYSVITA, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flector, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, Licart, MINIMED 780G, MOUNJARO, NP Thyroid 60, Omnipod, Ozempic, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, STRENSIQ, TEPEZZA, TRYNGOLZA, TWIIST, TZIELD, Tirosint, XYOSTED, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error